Tanabe et al., Cancer Res 1991
:
ICRF-193 , the most potent inhibitor, however, did not inhibit topoisomerase I at concentrations up to 300 microM
Cummings et al., Anticancer Drug Des 1996
(Carcinoma, Non-Small-Cell Lung...) :
NU/ICRF 505 is a tyrosine conjugate of anthraquinone modified at the C terminus of the amino acid as an ethyl ester and it stabilizes topoisomerase I (topo I)-cleavable complexes